中国在世界製造过程中的地位（2023）：中国新地位与现有地区製造能力和产出比较（第二版）

本报告分析了快速增长和变化的中国生物製药行业的趋势信息和未来前景，并与之前发布的年度报告（《生物製药产能和产量分析》）进行了比较。 □利用汇总数据，我们认为新的市场趋势和未来机会。

特殊细分：分析与意见部分行业分析师的评论

本报告比较了中国和世界其他地区生物製药製造行业的分析结果，提供了过去趋势的信息，同时展望了整个行业的前景。

• 由行业专家审核
• 专家分析
• 所有 66 页
• 涵盖所有 14 个行业
• 主要人物

分析范围

• 生物製药製造的主要趋势（2023 年）
• 初级重组蛋白的平均成本
• 单克隆抗体 (mAb) 的抗体滴度：按生产规模分类
• 当前产能利用率
• 当前产能限制
• 下游生物加工步骤对整体生产能力造成限制
• 避免产能受到重大限制的关键领域
• 未来 12 个月预算和资金比率的变化
• 过去 12 个月为降低总体生物工艺成本而采取的行动
• 一次性/一次性生物製造系统
• 未来 12 个月製造外包支出的变化
• 其他

An Invaluable Resource for Trends & Analysis

An in-depth review of emerging trends and opportunities, with comparative, aggregated data from BioPlan's 20^th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, providing trend information and relevant new in-depth insights into the rapidly growing and changing Chinese biologics industry.

SPECIAL SEGMENTS: Industry Reviewers' Comments in Analysis and Implications Sections.

This Report compares biomanufacturing industry insights in China with the rest of the world, and allows us to provide an insight into historical trends while keeping an eye on the outlook of the industry overall.

• Reviewed by Industry Experts
• Subject Matter Expert analysis
• 66 Pages
• 14 Segments covered
• Key Graphs and Tables

COVERAGE:

• Key Biomanufacturing Trend of 2023

• Average Cost for Primary Recombinant Protein

• Titer Ranges for mAbs at Various Production Scales

• Current Percent of Total Capacity for Facility Operation

• Capacity Constraints Today

• Downstream Bioprocessing Steps Creating Overall Capacity Constraints

• Important Areas to Avoid Significant Capacity Constraints

• Budget and Funding Percentage Changes over the Next 12 Months

• Actions to Reduce Overall Bioprocessing Costs During Past 12 Months

• Single-use/Disposable Biomanufacturing Systems

• Change in Spending on Outsourcing for Manufacturing Next 12 Months

• And More!